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Abstract: Myasthenia gravis (MG) is an autoimmmune disease in which autoantibodies to 
  different antigens of the neuromuscular junction cause the typical weakness and fatigability. 
  Treatment includes anticholinesterase drugs, immunosuppression, immunomodulation, and 
thymectomy. The autoimmune response is maintained under control by corticosteroids frequently 
associated with immunosuppressive drugs, with improvement in the majority of patients. In case 
of acute exacerbations with bulbar symptoms or repeated relapses, modulation of autoantibody 
activity by plasmapheresis or intravenous immunoglobulins provides rapid improvement. Recently, 
techniques removing only circulating immunoglobulins have been developed for the chronic 
management of treatment-resistant patients. The rationale for thymectomy relies on the central 
role of the thymus. Despite the lack of controlled studies, thymectomy is recommended as an 
option to improve the clinical outcome or promote complete remission. New videothoracoscopic 
  techniques have been developed to offer the maximal surgical approach with the minimal invasive-
ness and hence patient tolerability. The use of biological drugs such as anti-CD20 antibodies is still 
limited but promising. Studies performed in the animal model of MG demonstrated that several 
more selective or antigen-specific approaches, ranging from mucosal tolerization to inhibition of 
complement activity or cellular therapy, might be feasible. Investigation of the transfer of these 
therapeutic approaches to the human disease will be the challenge for the future.
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Background
Myasthenia gravis (MG) is an autoimmune disorder characterized by fluctuating 
muscle weakness and fatigability on exertion, in which autoantibodies to proteins of 
the neuromuscular junction (NMJ) are pathogenically relevant.1 To date 2 major types 
of antibodies are routinely detectable, ie, antibodies against the acetylcholine receptor 
(AChR) and to a muscle specific kinase (MuSK). Anti-AChR and anti-MuSK antibodies 
significantly interfere with neuromuscular transmission, and their removal produces 
clinical improvement; moreover, their pathogenic role has been confirmed in experimen-
tal models of MG.2,3 Anti-AChR autoantibodies are detected in about 80% to 85% of 
patients with generalized MG.1 According to series from different countries variable 
proportions of patients without anti-AChR antibodies have antibodies to MuSK.4 MG 
patients without antibodies to either AChR or MuSK are now defined as affected with 
“seronegative MG”. A recent study reported that 66% of seronegative myasthenic patients 
have low-affinity antibodies to AChR that cannot be detected by common assays.5
The NMJ, the synapse connecting nerve and muscle, works through the release 
of acetylcholine (ACh) and its engagement with the receptor on the muscle endplate. Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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In MG the neuromuscular transmission is impaired because 
of a reduced number of functional AChRs. At least 3 
antibody-mediated mechanisms have been proposed to 
explain AChR impairment: accelerated endocytosis and 
degradation of AChR; functional blockade of ACh-binding 
sites; and complement-mediated damage of the postsynaptic 
membrane. B cells are directly involved in AChR-antibody 
production and AChR-specific T cells are considered relevant 
for pathogenesis of MG. The pathogenicity of anti-MuSK 
antibodies has been a matter of debate; however, MuSK is 
necessary for the agrin-mediated clustering of AChR on the 
surface of postsynaptic muscle during development. More 
recently it has been shown that passive transfer of IgG from 
anti-MuSK-positive patients can cause myasthenia when 
injected into mice; moreover, both reduction of AChR 
density and loss of the normal apposition between pre- and 
postsynaptic structures were reported.6–8
Thymic abnormalities are frequently present and 
  specifically associated with MG; AChR antibody-positive 
MG patients show pathological abnormalities (either non-
  neoplastic or neoplastic) of the thymus in nearly 75% of 
cases.9 MG is associated with pathological abnormalities of 
the thymus gland in about 80% to 85% of cases and thymo-
mas have been reported with variable frequencies, in up to 
30% of MG patients.
The thymus is suspected to be the main site of autosensiti-
zation to AChR, since thymic epithelial cells and muscle-like 
(myoid) cells express AChR on their surface. AChR-specific 
T cell lines can be cloned from the thymus, cultured thymic 
lymphocytes produce AChR-specific autoantibodies, and 
numerous germinal centers are   present within the thymic 
medulla. However, what triggers autosensitization remains 
a mystery. Viral involvement has been suspected for a long 
time but without a definite   conclusion. In this regard, we 
have already shown that Toll-like receptor 4 (an activator 
of the innate immune response) is overexpressed in the 
thymus of some MG patients.10 More recently, we demon-
strated Epstein-Barr virus persistence and reactivation in MG 
thymus, suggesting again that a dysregulated infection may 
contribute to the initiation or perpetuation of the autoimmune 
response underlying the disease.11
Thymoma, usually a benign epithelial tumor, is found in 
about 10% to 20% of MG patients, depending on the series 
reported. Thymoma-associated MG is considered a more 
severe disease compared with nonthymomatous MG and its 
outcome relies mainly on prolonged immunosuppressive 
treatment.12,13
MG is a relatively rare disease whose incidence and 
prevalence rates have increased over the past 4 to 5 decades.14 
The annual MG incidence is reported to be about 2 to 21 per 
million per year and the prevalence about 200 per million.15,16 
The incidence is age- and sex-related: a peak in the second 
and third decades is observed among women, and in the 
sixth and seventh decades among men. MG may be under-
diagnosed in the elderly.17–19
MG is a chronic disorder, can be extremely severe, but is 
a treatable disease. Elucidation of the pathogenetic mecha-
nisms of MG has provided a rationale for   optimization of 
treatments (Figure 1). The therapeutic approach involves 
3 different lines: 1) drugs improving neuromuscular trans-
mission, ie, symptomatic therapies; 2)   immunomodulating 
drugs interfering with autoantibody activity on NMJ, 
ie,   corticosteroids, immunosuppressants and therapies 
  modulating circulating autoantibodies (apheresis or intrave-
nous immunoglobulins); and 3) modification of the natural 
history of the disease, eg, thymectomy.
In this review we will summarize and describe each of 
these lines of treatment, providing what is the state of the art 
of current treatments and new emerging approaches.
Treatment of myasthenia gravis
Effectiveness of treatment in MG must rely on definite 
  outcomes as was clearly defined by the Myasthenia Gravis 
Association of America Task Force in 2000. The ultimate goal 
is to achieve complete stable remission, defined as no myas-
thenic symptoms or signs without any ongoing   treatment for 
at least 1 year.20,21 Therapies in MG should therefore eliminate 
patients’ symptoms within the boundaries of adverse events 
associated with treatment itself.22
Several subtypes of MG have been recognized on the 
basis of age at onset, weakness distribution, thymus   histology, 
and presence of autoantibodies.16 These subgroups have a 
  different prognosis and need distinct therapeutic strategies. 
Although treatment options in MG are   considered   effective 
and underpinned by scientific evidence (see   Figure 1), 
  controlled clinical trials are rare leading to limited evidence- 
based information.23 Current guidelines are based largely 
on clinical experience, consensus between experts, and 
  retrospective analysis. At present adequate MG treatment 
usually permits a substantially full, productive life.
Drugs improving neuromuscular 
transmission
In 1934, physostigmine, an acetylcholinesterase (AChE) 
inhibitor, was used for the first time for the treatment of a 
myasthenic patient; it was then substituted by   pyridostigmine 
bromide (PB) in 1954. Oral AChE inhibitors are the first-line 
treatment for MG. They are symptomatic drugs improving Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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neuromuscular transmission by prolonging the availability of 
ACh at NMJ and do not interfere with the immune processes 
that cause and perpetuate MG. AChE inhibitors have a short-
term benefit due to their short half-life. European guidelines 
indicate that AChE inhibitors should be considered as first-line 
treatment for MG, particularly for mild cases.23 They may also 
be used as adjunctive treatment in patients with more severe 
disease also receiving other treatment modalities. PB is the 
most commonly used AChE inhibitor; its effect begins within 
30 minutes, peaks at about 2 hours and lasts for 3 to 4 hours; 
however, patients may display different individual responses, 
hence the physician may have to adjust for the optimal dose 
and the right interval in each patient.
PB is available as:
○	 An oral standard tablet, dose 60 mg; this is the most 
commonly used preparation.
○	 A sustained-release preparation (180 mg);24 usually pre-
scribed at bedtime for patients symptomatic during the 
night or in the early morning. A switch from instant to 
sustained-release PB as been proposed but still not fully 
investigated.24
○	 A syrup (12 mg/mL) for pediatric use, in patients 
  requiring nasogastric feeding or, very rarely, in those 
patients with allergic reactions to drug excipients.
○	 PB is also available for intramuscular or intravenous 
administration in the form of 2-mL ampules,   containing 
5 mg/ml of the drug. About 1/30 of the oral dose of 
PB may be given parenterally for an equivalent effect. 
  Parenteral administration is useful when patients cannot 
take   therapies orally. Few patients have experienced 
  significant, sometimes fatal, cardiac arrhythmias;25,26 hence 
intramuscular administration should be preferred.
The dosage schedule must be adjusted according to 
the clinical status of the patient. The initial oral dose in 
adults consists of 30 to 60 mg every 4 to 6 hours. Patients 
requiring more than recommended doses for adequate 
relief of symptoms are candidates for other modalities of 
treatment.
Neonatal MG occurs in about 10% of babies born from 
MG mothers due to placental transfer of maternal AChR-
antibodies.27 AChE inhibitors may be used temporarily until 
MG resolves spontaneously after a few weeks.
Other AChE inhibitors:
○	 Neostigmine is an analog of PB and can be adminis-
tered orally, while neostigmine methylsulfate is given 
intramuscularly or intravenously. Compared with PB, 
neostigmine has a shorter action, is less effective and 
more frequently cause muscarinic side effects.28,29
○	 Ambenonium chloride is rarely used because of its long 
duration of action and greater tendency to accumulate.
○	 Edrophonium is a very short-acting AChE inhibitor and 
is used mainly for diagnostic testing.
Thymectomy
Steroids
Immunosuppressants:
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Figure 1 The immunopathological steps of myasthenia gravis (MG) are summarized as well as the specific targets of therapeutic intervention. In red are outlined the 
innovative therapeutic approaches.
Abbreviations: Ab, antibodies; AChR, acetylcholine receptor; AChe, acetylcholinesterase; ivig, intravenous immunoglobulins; MMF, mycophenolate mofetil; MuSK, muscle 
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AChE inhibitors are generally well tolerated; common 
adverse effects are mainly due to cholinergic stimulation of 
muscarinic AChR on smooth muscle and autonomic glands. 
They occur in about one-third of the patients.30,31 The most 
frequent are gastrointestinal disorders, such as gut hypermo-
tility, which may lead to abdominal pain and diarrhea; other 
side effects are increased sweating and bronchial secretion 
(sometimes patients experience symptoms mimicking bron-
chial asthma); bradycardia and hypotension are seen more 
frequently in elderly patients. Side effects can be controlled 
by oral or parenteral administration of atropine (0.5 to 1 mg 
in adults and 0.01 mg/kg in children). Patients carrying a 
polymorphism in the promoter gene encoding the catalytic 
subunit of AChE show acutely exaggerated sensitivity to 
conventional doses of AChE inhibitors.32 Nicotinic cholin-
ergic side effects are less frequently observed and occur in 
patients receiving high doses of AChE inhibitors: muscle 
fasciculations, cramps, and blurred vision are the most com-
mon. Older patients (over 60 years) are more prone to develop 
cholinergic side effects, while duration of treatment does not 
correlate with side effects.31 AChE inhibitors may be stopped 
in the course of a myasthenic crisis to reduce bronchial and 
salivary secretions;33–35 they will be reintroduced when the 
patient starts to improve and is ready to be extubated.
Randomized placebo-controlled trials on the efficacy of 
AChE inhibitors are not available, but case series and daily 
clinical experience have shown an objective and marked 
clinical effect.23
AChE inhibitors are relatively ineffective in the treatment 
of ocular MG: patients shift to other treatments, in particular 
corticosteroids, which are very effective in ocular MG.22
MG associated with MuSK-antibodies is often more severe 
than AChR-positive MG and its response to AChE inhibitors 
is usually insufficient: a high proportion of patients need 
immunosuppressive treatments.36 AChE inhibitors are poorly 
tolerated: muscle cramps, fasciculations,37,38 and extra dis-
charges with low-frequency motor nerve stimulation have been 
described, suggesting an abnormal sensitivity to ACh.31,38
AChE inhibitors are safe during pregnancy.39,40
Immunomodulating therapies 
interfering with autoantibody 
effects on NMJ
Conventional and emerging therapies able to interfere with 
the immunopathogenetic processes underlying MG comprise 
the following:
1.  Steroids;
2.  Immunosuppressants;
3.  Immunomodulating agents;
4.  Biological and cellular therapies.
Steroid and immunosuppressants are usually used on 
chronic therapeutic regimen, whereas immunomodulating 
agents are usually adopted as short-term therapies.
Steroids
Oral steroids are widely used in MG and are recommended 
as a first-choice drug when immunosuppression is required.23 
Notwithstanding their extensive usage, the potential for 
severe side effects is high and a significant impact on patients’ 
quality of life is foreseen.9
A variety of steroids has been used in the treatment of MG: 
the most commonly used is prednisone because of its potent 
immunosuppressive activity, low anti-edemigen activity and 
half-life compatible with an alternate-day schedule.41
Retrospective data indicate that prednisone provides a 
clinical benefit in about 80% of patients;42,43 its effectiveness 
was confirmed in a systematic Cochrane review.44
The initial dose for the treatment of generalized MG 
is 1 mg/kg/day. Patients with moderate-to-severe general-
ized MG are usually hospitalized to initiate steroid therapy 
because of the risk of a drug-induced exacerbation of the 
disease; exacerbation may start within the first 2 weeks of ste-
roid treatment and may be extremely severe. Steroid-induced 
clinical improvement usually begins within 2 to 4 weeks. 
Different modalities of steroid initiation have been proposed: 
patients’ condition permitting, the best approach is to start 
steroid treatment with the highest daily dosage, followed 
by the shift to an alternate-day regimen and later on, when 
pharmacological remission or minimal manifestations state 
are achieved, the search for the minimal effective dose should 
be pursued.43 Ocular MG usually requires lower dosages, 
however resistant forms may require higher doses to be 
effective. A recent study suggested that immunotherapy of 
ocular MG reduces conversion to generalized MG; however, 
the reported series were retrospective and a selection bias 
cannot be excluded; prospective observational studies should 
be designed to address this important issue.45,46
Side effects of chronic corticosteroids are osteoporosis, 
cataract, diabetes mellitus, hypertension, gastrointestinal 
irritation, glaucoma, weight gain, and skin disorders.
immunosuppressants
Several immunosuppressive drugs are used in the treatment 
of MG: usually the time to achieve a clinical benefit with 
these drugs is longer than that of steroids and can take several 
months. They can be used as single drugs, as an alternative Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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therapy to steroids in those patients with contraindications to 
it, or frequently used in combination with corticosteroids as 
“steroid-sparing agents”.9,23 RCT demonstrating the efficacy 
of immunosuppressive drugs in MG is very limited: larger, 
longer and well-designed clinical trials are warranted.47
Azathioprine (AZA)
Azathioprine is the most frequently used immunosuppres-
sive drug for MG, because of its preferential effect on T 
cell replication, with evidence supporting a steroid-sparing 
effect.20,23,48 The daily dose is 2–3 mg/kg/day. AZA efficacy 
has been   confirmed in a randomized clinical trial (RCT).48 
It is generally well tolerated, but liver and bone marrow 
toxicity is not infrequent. The use of AZA may be optimized 
by a pharmacogenomic approach by testing TPMT gene 
polymorphisms.49
Cyclosporin A (CyA)
Cyclosporin A inhibits the production of interleukin (IL)-2 
by helper T cells. CyA efficacy was confirmed by a RCT for 
MG,50 but its use was hampered by the onset of hypertension 
and nephrotoxicity. CyA is therefore considered a   third-line 
therapy and should be used only in patients intolerant or 
  unresponsive to other immunosuppressants; monitoring of 
kidney function, blood pressure and detection of CyA plasma 
levels is necessary. A frequent and intractable side effect is 
tremor which disappears after discontinuation of the drug. The 
recommended daily dosage is 5 mg/kg/day twice daily.
Cyclophosphamide
Cyclophosphamide acts mainly on B lymphocytes and was 
demonstrated to be effective in treatment-resistant MG 
cases;47,51 however, its use is limited by the risk of adverse 
side effects, including late development of malignancies or 
infertility, to patients intolerant or non-responsive to other 
treatment modalities.23
Mycophenolate mofetil (MMF);  
tacrolimus (FK506)
These are newer immunosuppressive drugs that may have 
some benefit as second-line immunosuppressive therapy23 
although this was not supported by a recent systematic 
review.47 Two recent randomized controlled studies did not 
demonstrate a clear efficacy of MMF in MG patients;52,53 it 
is likely that the limited duration of the study (9 months) 
did not allow a correct assessment of the efficacy of MMF 
in patients already taking pharmacological doses of pred-
nisone. Although the MMF clinical trials were considered 
negative, they provided relevant clinical and pharmacological 
  information with regard to the design and the methodological 
aspects of RCTs in MG, eg, it will be necessary to rethink 
how to set up studies comparing the efficacy of a new immu-
nosuppressive drug in comparison to steroid.
Methotrexate
No studies are available on the use of methotrexate in MG. 
However, the drug can be considered in treatment-resistant 
patients when all other treatment options have been tried. 
Long-term toxicity should be always considered. A Phase II 
clinical trial is under way (see www.clinicaltrials.gov).
Short-term immunomodulation: 
plasma-exchange and intravenous 
immunoglobulins
Plasma-exchange (PE) and intravenous immunoglobulins 
(IVIg) are generally used to induce a rapid improvement in 
patients with exacerbation of the disease. Their beneficial 
effect is rapid, but only temporary, lasting for 4 to 5 weeks.
PE is usually performed by exchanging 1 plasma volume 
on alternate days. In our experience, a 2-course treatment is 
usually sufficient to induce clinical improvement,54 although 
in some cases it may be necessary to repeat more courses 
according to the patients’ clinical conditions. Methodologi-
cal flaws related to open studies on PE have been underlined 
in the Cochrane review on this topic.55 Nevertheless, open 
studies showed that PE was effective in at least 60% to 70% 
of treated patients and that improvement was strictly related 
in time with plasma removal. The main indication to PE, as 
well as intravenous immunoglobulins, is the acute worsen-
ing of the disease (either severe generalized or bulbar) or 
myasthenic crisis. Other indications include worsening during 
the start of corticosteroids, and preparation to thymectomy 
in symptomatic patients. On the basis of our experience we 
think there is no need to perform PE immediately before 
thymectomy when MG is well controlled by pharmacologi-
cal treatment. The chronic use of PE in MG has never been 
addressed with a definite protocol. Nevertheless, PE can be 
used at repeated intervals in selected patients in case of fre-
quent relapses, when the response to pharmacological treat-
ment is unsatisfactory after an adequate clinical follow-up, 
or in patients who have major contraindications to long-term 
corticosteroids. Limitations to the use of chronic PE are the 
need for good vascular accesses and the obvious effects on 
several plasma components in case of intensive protocols. 
Therefore, the number of sessions and interval between 
them must be tailored to each patient, taking into account Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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the general clinical conditions, severity of MG, and potential 
side effects. Because of these limitations, immunoglobulin G 
(IgG) apheresis should be the technique of choice in severe 
immunosuppression-resistant patients requiring chronic 
treatments.
MuSK-positive MG shows a dramatic response to PE (or 
IVIg).37 This feature is of particular importance in the effort 
to overcome the prolonged and severe bulbar involvement 
that frequently occurs in this subset of MG patients. The 
reason for this clinical behavior is still unclear but is likely 
related to the activity of anti-MuSK antibodies that do not 
bind complement, as occurs with anti-AChR antibodies, 
and therefore might cause a different kind of damage to the 
neuromuscular junction.
IVIgs are usually administered at a dose of 400 mg/kg 
body weight/day for 3 to 5 days.56,57 IVIgs have been com-
pared with PE in RCTs,55,58 showing a significant clinical 
improvement within 2 weeks with no substantial difference 
between the two treatment options. A recently published 
trial found no significant superiority of 2 g/kg over 1 g/kg 
of IVIgs in the treatment of MG exacerbation.56
Thus, PE and IVIg have a similar efficacy; PE is less 
expensive, but requires specific equipment and side effects 
are a little more common.23,58 Since good vascular access is 
mandatory for PE, IVIg represents a good alternative for chil-
dren and older patients. As reported above for PE, IVIgs are 
suitable for chronic treatment of patients with unsatisfactory 
response to ongoing pharmacological treatments. Long-term 
protocols have not been investigated in detail.59
Semiselective immunoadsorption
The ideal apheretic approach should remove only the specific 
autoantibody involved in the pathogenesis of the disease 
under treatment, leaving all the other plasma components 
unaltered, a specific approach not yet available for clinical 
practice. A compromise is represented by circulating IgG 
immunoadsorption (IA), a procedure able to remove IgG and 
hence specific autoantibodies. Two main ligands are avail-
able for clinical use in IgG-mediated disorders. Protein A is a 
component of the staphylococcal cell wall that binds human 
IgG with high affinity.60 A second method involves the use 
of polyclonal sheep anti-human IgG that removes directly 
circulating IgG by means of an immunological interaction.61 
In both cases, plasma is separated by centrifugation and then 
passed on-line through a set of 2 filters filled with either 
protein A or sheep antihuman IgG, continuously regenerated 
throughout the procedure allowing removal of unlimited 
amounts of antibodies. No replacement fluid is needed and 
the interaction with coagulation factors is negligible. At least 
2 plasma volumes are treated during each session to fully 
exploit the binding capacity of the filters. We favor the use 
of IA in patients with severe treatment-resistant MG after 
adequate clinical follow-up, patients who require frequent 
PE to keep a satisfactory improvement, or patients who have 
major contraindications to the use of high dose corticosteroids 
or other immunosuppressive drugs.
Thymectomy
Thymectomy is mandatory in patients with thymoma and is 
recommended as an option for nonthymomatous patients with 
generalized MG, in particular those with acetylcholine anti-
bodies and younger than 60 years, to increase the likelihood of 
remission or improvement.23,62,63 Several surgical techniques 
have been proposed but there is general agreement on the 
maximal approach, ie, extended trans-sternal thymectomy. 
In recent years, variations in videothoracoscopic techniques 
have been developed, with either unilateral (video assisted 
thoracoscopic surgery) or bilateral access to the mediasti-
num (video assisted thoracoscopic extended thymectomy). 
In our experience, the use of thoracoscopic thymectomy in 
nonthymomatous MG was comparable to that of the clas-
sical trans-sternal approach; complete stable remission was 
50.6% at 6 years of follow-up. Compared with trans-sternal 
surgery, videothoracoscopic thymectomy is associated with 
less morbidity and negligible esthetic sequelae.64
The advantage of thymectomy is the chance of long-term 
benefit reducing or, in some cases, stopping the ongoing 
chronic medical therapies. However controlled studies dem-
onstrating the benefit of thymectomy are not available. An 
international, prospective, single-blinded randomized trial of 
thymectomy in nonthymomatous MG patients is currently 
ongoing. The role of thymectomy in patients with purely 
ocular disease is unclear.65,66
New treatment options
Innovation in MG treatment relies mainly on the following 
aspects: a) the need for new effective therapies that will 
combine adequate efficacy, reduction of side effects, and use 
of therapeutic schedules optimized for chronic immunosup-
pression; b) use of drugs with higher specificities targeting 
selectively the critical immunopathological steps from AChR 
sensitization to autoantibody production. Most of this search 
has been achieved through the use of the animal model of 
MG (EAMG) and the big issue is the translation from the 
relatively homogeneous condition of the experimental model 
to the very heterogeneous condition typical of human MG.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Table 1 lists new treatment options, showing their use in 
EAMG and human disease.
Rituximab
Rituximab is a humanized monoclonal antibody to CD20 that 
causes prolonged B-cell depletion approved for treatment of 
B-cell lymphoma in adults, and has been used in refractory 
MG. Small series of patients are available, and both MG with 
and without thymoma have been treated. Rituximab provides 
promising expectations for the treatment of MG,67–70 although 
no RCTs have been conducted so far.
etanercept
Etanercept blocks tumor necrosis factor-α (TNFα) activity 
and has been shown to suppress ongoing EAMG.71 Etaner-
cept was used in a prospective pilot trial in corticosteroid-
dependent autoimmune MG: 70% of patients who completed 
the trial improved their muscle strength and lowered corti-
costeroid requirement. A direct correlation between plasma 
IL-6, TNF-α, and interferon-γ levels and post-treatment 
clinical scores of the patients was found.72,73 However dis-
ease worsening was seen in some patients and MG has been 
also observed during treatment of rheumatoid arthritis with 
etanercept through a RCT.
Complement inhibitors
The role of complement in the pathogenesis of MG is well 
established; indeed, complement activation by specific autoan-
tibodies is involved in the attack to the NMJ, as demonstrated 
by localization of C3 activation fragments and membrane 
attack complex. Recently, administration of a complement 
inhibitor to experimental MG animals reduced the severity 
of the disease as well as complement deposition at neuromus-
cular end-plates; these observations are of great interest for a 
potential application in humans.74
Oral and nasal tolerance
Oral tolerization to the AChR has been achieved in rats 
using recombinant fragments of the AChR alpha subunit and 
in mice with synthetic peptides corresponding to the main 
immunogenic epitopes of the AChR.75,76 Both approaches 
were able to reduce the clinical manifestations of the disease 
in   experimental animals as well as specific autoantibodies. 
Different mechanisms have been postulated, according 
to the route of administration, dosage (high vs low dose) 
and   schedule. Induction of anti-inflammatory   cytokines 
(  particularly transforming growth factor-β) has been observed 
in tolerized animals. Tolerization has also been induced by 
the nasal delivery of the antigen. However, the potential 
transfer of these protocols to humans implies the availabil-
ity of large amounts of nonimmunogenic   autoantigens or 
recombinant fragments of the original molecule.
Modulation of AChe expression
Innovation in the symptomatic therapy of MG involves the 
use of oral antisense oligonucleotides able to cause targeted 
gene transcription inhibition, thus interacting with specific 
complementary mRNA: EN101 antisense (Monarsen) 
reduces the levels of read through splicing variant of AChE. 
Preliminary results from a phase Ib clinical trial seem to be 
promising;77,78 in particular the effect of EN101 seems to last 
for more than 24 hours, providing the obvious advantage of 
a single daily administration.
Cellular therapy
A further perspective for specific immunotherapy in MG 
may derive from the manipulation of professional antigen-
  presenting cells (dendritic cells) by AChR   proteins or   peptides 
or by the mobilization of antigen-specific   regulatory T cells; 
these therapeutic approaches were shown to be   effective 
in preventing the induction of or in treating EAMG.79–81 
  However, transfer of such cellular treatments to human beings 
needs to address several technical and production issues, such 
as cell specificity, amount of cell production, and good manu-
facturing practice, which are not yet fully addressed.
Specific anti-AChR removal
Expression of the extracellular domains (ECD) of the 
different subunits of the AChR by molecular biology tech-
niques provided the basis for a specific removal of anti-AChR 
antibodies. Indeed, these recombinant ECDs were coupled 
to insoluble carriers which were used to immunoadsorb 
antibodies derived from MG patients. Anti-AChR antibodies 
were depleted and the procedure was sufficiently efficient to 
Table 1 Biological drugs and experimental treatments tested in 
animal model of myasthenia gravis (eAMG) or human myasthenia 
gravis (MG)
Treatment EAMG Human MG
Anti-CD20 + +
Anti-TNF-α + +
Oral tolerance + nd
DC treatment + nd
Ag-specific apheresis nd in vitro only
Complement inhibitors + nd
Treg treatment + nd
AChe modulation + +
Abbreviations:  AChe,  acetylcholinesterase;  Ag,  antigen;  DC,  dendritic  cells; 
nd, not done; TNF, tumor necrosis factor; Treg, regulatory T cells.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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eliminate pathogenic factors from MG sera, thus proving the 
feasibility of the procedure.82 Further improvements will be 
necessary to increase the efficiency of antibody removal and 
to scale up the procedure to undergo proper clinical trials.
Reduction of AChR modulation  
at the NMJ
Reduction of antigenic modulation was attempted in EAMG 
using different approaches: a) by increasing the expression 
of rapsyn, a protein essential for the proper anchoring of 
the AChR at the NMJ; b) by functional competition of 
  monovalent IgG4 anti-AChR antibodies. Both approaches 
were successful in preventing MG disease activity.83,84
MG, although a rare disease, has become a prototype 
extensively studied for the identification of the immunop-
athogenetic mechanisms underlying autoantibody-mediated 
diseases. The investigation of experimental models, clinical 
practice (some times dated back to the 1980-1990's), the 
development of clinical reaserch, and technological innova-
tion have generated a rationale flow-chart for MG treatment 
(see Figure 2) which considerably improved the prognosis 
of patients and widened the perspective of more specific and 
selected therapeutic approaches.
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